Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced Asthma

Trial Profile

Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced Asthma

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Torii Pharmaceutical
  • Most Recent Events

    • 18 Aug 2015 According to an ALK-Abello media release, the New Drug Application submitted by its partner, Torii, to the Japanese Ministry of Health, Labour and Welfare has been accepted for review.
    • 02 Sep 2014 Based on results of this trial and the second pivotal trial, Torii Pharmaceuticals is expected to submit a registration application in Japan within 6 months, according to an ALK-Abello media release.
    • 16 Jun 2014 Primary endpoint 'Risk of moderate to severe asthma exacerbations' has not been met according to the ALK-Abello media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top